EU/LA Pearl Index Study - Transdermal Contraceptive Patch
Launched by BAYER · Jun 4, 2009
Trial Information
Current as of June 17, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Requiring contraception
- • Normal cervical smear
- • Smokers not older than 30 years
- • History of regular cyclic menstrual periods
- Exclusion Criteria:
- • Pregnancy or lactation
- • Obesity (BMI\> 30 kg/m2
- • Significant skin reaction to transdermal preparations or sensitivity to surgical / medical tape
- • Any disease that may worsen under hormonal treatment (cardiovascular, liver, metabolic)
- • Use of other contraceptive methods than study medication
About Bayer
Bayer is a global healthcare and life sciences company dedicated to advancing health and well-being through innovative research and development. With a strong commitment to improving patient outcomes, Bayer conducts clinical trials across various therapeutic areas, including oncology, cardiology, and women's health. The company leverages cutting-edge science and technology to develop breakthrough therapies, while adhering to the highest standards of ethical practices and regulatory compliance. Through collaboration with healthcare professionals and research institutions, Bayer aims to bring transformative solutions to the market, ultimately enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, , Italy
Barcelona, , Spain
Barcelona, , Spain
Adelaide, , Australia
Pisa, , Italy
Magdeburg, Sachsen Anhalt, Germany
Leipzig, Sachsen, Germany
Pavia, , Italy
Siena, , Italy
Nimes, , France
Dresden, Sachsen, Germany
Modena, , Italy
Nedlands, Western Australia, Australia
Palermo, , Italy
Clayton, Victoria, Australia
Firenze, , Italy
Leipzig, , Germany
Biarritz, , France
Montargis, , France
Saint Germain En Laye, , France
San Fernando, Cádiz, Spain
Köln, Nordrhein Westfalen, Germany
Catanzaro, , Italy
Cagliari, , Italy
Toulouse, , France
Jessen, Sachsen Anhalt, Germany
Dresden, Sachsen, Germany
Berlin, , Germany
Dippoldiswalde, Sachsen, Germany
Magdeburg, Sachsen Anhalt, Germany
Gera, Thüringen, Germany
México D.F., , Mexico
Rosario, Santa Fe, Argentina
Perugia, , Italy
Blankenburg, Sachsen Anhalt, Germany
Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina
Pavia, Lombardia, Italy
Quetigny, , France
Chihuahua, , Mexico
Wuppertal, Nordrhein Westfalen, Germany
Siegen, Nordrhein Westfalen, Germany
Lanus Oeste, Buenos Aires, Argentina
San Isidro, Buenos Aires, Argentina
Reims Cedex, , France
Torreón, Coahuila, Mexico
México, D.F., , Mexico
Frankfurt, , Germany
Ashfield, New South Wales, Australia
North Adelaide, South Australia, Australia
Mexico D.F., , Mexico
Berlin, , Germany
Francavilla Fontana, Brindisi, Italy
Köln, Nordrhein Westfalen, Germany
Temuco, Araucanía, Chile
Santiago, , Chile
Aachen, Nordrhein Westfalen, Germany
Mexico D.F., , Mexico
San Luis Potosí, , Mexico
Vigo, Pontevedra, Spain
Dos Hermanas, Sevilla, Spain
Alava, Vitoria, Spain
Lugo, , Spain
Pamplona, , Spain
Zaragoza, , Spain
Patients applied
Trial Officials
Bayer Study Director
Study Director
Bayer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials